Patients Come First spokesperson on 340B rebate model: ‘This rebate model provides the oversight that 340B has needed for decades’

Patients Come First spokesperson on 340B rebate model: ‘This rebate model provides the oversight that 340B has needed for decades’
Kasia Mulligan, Spokesperson for the Patients Come First — Provided photo
0Comments

Kasia Mulligan, national spokesperson for Patients Come First, said the 340B rebate pilot program introduces oversight and ensures drug savings directly benefit patients. The statement was made in an op-ed.

“The lack of transparency and accountability measures in the current discount model has enabled hospitals to pocket the discounts, intended for patients, and divert the savings to fund unrelated projects, such as infrastructure improvement,” said Mulligan. “So much that 83 percent of people support reforming the program to ensure those savings reach the patients who need them most. This rebate model provides the oversight that 340B has needed for decades, and nearly 80 percent of people agree it’s a powerful change to the status quo. Participating pharmaceutical companies are taking steps toward greater transparency, aiming to improve the patient healthcare experience and ensure cost savings reach those patients.”

Established in 1992 and administered by the Health Resources and Services Administration (HRSA), the 340B Drug Pricing Program was created to help healthcare providers stretch limited resources to serve vulnerable populations. It allows eligible entities to purchase outpatient drugs at reduced prices. These savings are intended to support access to care for low-income and uninsured patients.

A 2024 report by the National Alliance of Healthcare Purchaser Coalitions found that prices at large 340B hospitals were 35% higher on average for common outpatient services compared to non-340B hospitals. The study estimated that this pricing difference results in an added $36 billion annually in healthcare costs for employers. These findings were based on an analysis of commercial claims data from over 25 million American workers and their families.

PhRMA reported that 68 hospitals in Pennsylvania participate in the 340B drug discount program, holding over 2,250 contracts with pharmacies nationwide. Only 29% of these contract pharmacies are located in medically underserved areas. Additionally, 88% of participating hospitals in the state provide charity care below the national average, raising questions about the program’s reach and impact.

Kasia Mulligan is the national spokesperson for the consumer patient advocacy group, Patients Come First. The organization advocates for greater transparency, accountability, and patient-focused reforms in healthcare policy. Mulligan represents the group in public statements and written commentary on health system issues.



Related

John C. Gurganus Acting United States Attorney for the Middle District of Pennsylvania - Department of Justice

Lackawanna County man receives four-year sentence for art theft conspiracy

Joseph Atsus, 51, of Covington Township, Pennsylvania, was sentenced to 48 months in prison and ordered to pay $1,071,150 in restitution for his involvement in a conspiracy involving the theft and concealment of major artwork.

Stephen J. Ubl, CEO of the Pharmaceutical Research and Manufacturers of America - Provided photo

PhRMA warns of cancer drug markups, 340B program profiteering affecting Pennsylvania

The Pharmaceutical Research and Manufacturers of America (PhRMA) announced that hospital systems are marking up decades-old cancer drugs significantly above Medicare rates.

Troy Rivetti, U.S. Attorney%27s Office for the Western District of Pennsylvania - Department of Justice

Blawnox man sentenced to 20 years for sexual exploitation of a minor

A man from Blawnox, Pennsylvania, has pleaded guilty to federal charges related to the sexual exploitation of a minor and has been sentenced to 20 years in prison.

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from Keystone Today.